Hologic ((HOLX)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hologic, Inc. is currently conducting a clinical study titled ‘Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device.’ The study aims to collect de-identified contrast-enhanced breast images using a new mammography device to aid in the development of advanced software technology. This research is significant as it targets women over 35 who have suspicious findings on mammograms, potentially enhancing diagnostic accuracy and patient outcomes.
The intervention being tested is a device known as the CEM Software in a New Mammography Device. This experimental software is designed to improve the quality of mammography imaging, thereby assisting in better screening and diagnosis of breast abnormalities.
The study follows an interventional design with a single-group model and no masking. Its primary purpose is screening, focusing on collecting data to refine the mammography device’s software capabilities.
The study began on October 7, 2024, with the last update submitted on October 20, 2025. These dates are crucial as they indicate the study’s progress and the ongoing commitment to advancing breast imaging technology.
For investors, this study update from Hologic could signal potential growth in the company’s market share, particularly if the new device proves successful. As the company continues to innovate in breast imaging, it may positively influence its stock performance and investor sentiment, especially in comparison to competitors in the medical imaging industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.